<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715884</url>
  </required_header>
  <id_info>
    <org_study_id>P07-6330</org_study_id>
    <nct_id>NCT00715884</nct_id>
  </id_info>
  <brief_title>Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems</brief_title>
  <acronym>ELITE</acronym>
  <official_title>A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to show similar (non-inferior) safety and effectiveness
      between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a
      prospective, multi-center, randomized clinical study for the treatment of de novo native
      coronary lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-blind, randomized, multicenter, two arm study. The objective of this
      study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and
      CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center,
      randomized clinical study for the treatment of de novo native coronary lesions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Target Lesion Failure (TLF)</measure>
    <time_frame>12-months post-procedure</time_frame>
    <description>The primary endpoint for this study is the percentage of participants who experienced Target Lesion Failure (TLF) during the 12 months post-procedure. A TLF event is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Lesion Success</measure>
    <time_frame>At procedure</time_frame>
    <description>Lesion success is defined as the attainment of &lt; 50 percent residual stenosis (by Quantitative Coronary Angiography (QCA)) using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Device Success - Protocol Definition</measure>
    <time_frame>At procedure</time_frame>
    <description>Device success is defined as achievement of a final residual diameter stenosis of &lt;50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. Protocol definition: Only protocol-defined study stents were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Device Success - All CYPHER® Stents Included</measure>
    <time_frame>At procedure</time_frame>
    <description>Device success is defined as achievement of a final residual diameter stenosis of &lt;50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. All CYPHER® Stents were included if the final residual stenosis was &lt;50%. Non-study CYPHER® Stents were also included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Procedure Success</measure>
    <time_frame>At procedure during hospital stay</time_frame>
    <description>Procedure success is defined as achievement of a final diameter stenosis of &lt; 50 percent (by QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>TLR is defined as any &quot;clinically-driven&quot; repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic electrocardiogram (ECG) changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>TVR is defined as any &quot;clinically driven&quot; repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Target Vessel Failure (TVF)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Target Vessel failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>MAJOR ADVERSE CARDIAC EVENTS (MACE) consists of death, myocardial infarction, emergent bypass surgery, and target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Bleeding Complications</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Bleeding complications include any bleeding events defined by THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI), Global Strategies for Opening Occluded Coronary Arteries (GUSTO), and &quot;Protocol&quot; definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Died</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Death incidences include both Cardiac and non-cardiac death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Any Myocardial Infarction (MI)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Myocardial Infarction includes both Q-wave and WHO Non-Q Wave Myocardial Infarction events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Stroke</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>The stroke definition includes both hemorrhagic and non-hemorrhagic strokes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Protocol defined Stent thrombosis include both Early and Late Thrombosis. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave MI, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring &gt; 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site-reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition)</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Academic Research Consortium (ARC) defines STENT THROMBOSIS as consisting of the following:
DEFINITE - Angiographic or pathologic confirmation;
PROBABLE - Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent;
POSSIBLE - Any unexplained death &gt; 30 days.
ARC Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition)</measure>
    <time_frame>0-30 days post-procedure</time_frame>
    <description>Those ARC stent thromboses occurred between 0 and 30 days post-procedure are early stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition)</measure>
    <time_frame>31-360 days post-procedure</time_frame>
    <description>Those ARC stent thromboses occurred between 31 to 360 days post-procedure are late stent thrombosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER® ELITE™ Sirolimus-Eluting Stent System</intervention_name>
    <description>Drug eluting stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cypher ELITE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</intervention_name>
    <description>Drug eluting stent</description>
    <arm_group_label>2</arm_group_label>
    <other_name>CYPHER Bx VELOCITY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with de novo atherosclerotic CAD in 1 or 2 vessels;

          -  The subject must be &gt;/= 18 years of age;

          -  Female of childbearing potential must have a negative pregnancy test within 7 days
             prior to enrollment;

          -  Diagnosis of angina pectoris as defined by stable angina pectoris Canadian
             Cardiovascular Society Classification (Class I, II, III) OR non-ST segment elevation
             acute coronary syndrome (Braunwald Classification B&amp;C) OR non-ST segment elevation
             myocardial infarction &gt;/= 48 hours from the time of study index procedure OR
             asymptomatic subjects with a positive stress test;

          -  Treatment of &lt;/= two lesions in one or two major coronary arteries (1 target lesion in
             each of 2 vessels or 2 target lesions in 1 vessel);

          -  Target vessel diameter must be &gt;/= 2.25mm and &lt;/= 4.0 in diameter (visual estimate);

          -  Target lesion stenosis is &gt; 50% and &lt; 100% (visual estimate);

          -  Target lesion length &lt;30mm (for each target lesion(s)) with a total implanted stent
             length &lt; 66mm. Additional stents can be used to treat dissections, etc,: however,
             these must be the same stent to which the subject has been randomized in the study.

          -  Subject or Legally Authorized Representative must provide written informed consent
             prior to the procedure using a form that is approved by the Institutional Review
             Board/Independent Ethics Committee.

        Exclusion Criteria:

          -  ST Segment Elevation Myocardial Infarction (STEMI) within 30 days of the study index
             procedure;

          -  Unprotected left main coronary disease with &gt;/= 50% stenosis;

          -  Total coronary occlusion or TIMI grade 0 or 1 in the target vessel;

          -  Angiographic evidence of thrombus within target lesion(s);

          -  Calcified target lesion(s) which cannot be, in the investigator's opinion,
             successfully pre-dilated;

          -  Bifurcation disease involving a side branch &gt;/= 2 mm in diameter;

          -  Prior stent within 5 mm of target lesion(s);

          -  Ostial target lesion(s);

          -  Target lesion(s) within a coronary bypass graft (e.g., saphenous vein or arterial
             graft);

          -  Documented left ventricular ejection fraction &lt;/= 25%;

          -  Impaired renal function (creatinine &gt; 250 μmol/L or &gt; 2.5 mg/dl) at the time of
             treatment;

          -  Pretreatment with devices other than conventional balloon angioplasty;

          -  Significant angulation in the target vessel that, in the Investigator's opinion, may
             preclude stent delivery and deployment;

          -  Subject previously treated with brachytherapy;

          -  Recipient of heart transplant;

          -  Subject with a life expectancy less than 12 months;

          -  Known allergies to the following: aspirin, clopidogrel bisulfate and ticlopidine,
             heparin, stainless steel, contrast agent (that cannot be managed medically), or
             sirolimus that cannot be managed medically;

          -  Any significant medical condition which, in the Investigator's opinion, may interfere
             with the subject's optimal participation in the study;

          -  Currently participating in an investigational drug or device study that has not
             completed the primary endpoint or that clinically interferes with the study endpoints;

          -  In the Investigator's opinion, the lesion is not suitable for stenting;

          -  Known bleeding or hypercoagulable disorder;

          -  Known or suspected active infection at the time of the study procedures;

          -  Subject is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or
             drug abuser;

          -  Subject has had major surgical or interventional procedures unrelated to this study
             within 30 days prior to this study or planned surgical or interventional procedures
             within 30 days of entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lowell Satler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <results_first_submitted>February 25, 2011</results_first_submitted>
  <results_first_submitted_qc>April 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2011</results_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>de novo native coronary lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ELITE™</title>
          <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
        </group>
        <group group_id="P2">
          <title>CYPHER®</title>
          <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="452"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ELITE™</title>
          <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
        </group>
        <group group_id="B2">
          <title>CYPHER®</title>
          <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="452"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="678"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="10.5"/>
                    <measurement group_id="B2" value="62.2" spread="10.5"/>
                    <measurement group_id="B3" value="62.8" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="452"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with History of Previous Percutaneous Coronary Intervention (PCI)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Previous PCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of Previous PCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with History of Previous Coronary Artery Bypass Graft (CABG)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Previous CABG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of Previous CABG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="404"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with Family History of Coronary Artery (CAD)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Family History of Coronary Artery (CAD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Family History of Coronary Artery (CAD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with History of Hyperlipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="388"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with History of Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with History of Diabetes Mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Target Lesion Failure (TLF)</title>
        <description>The primary endpoint for this study is the percentage of participants who experienced Target Lesion Failure (TLF) during the 12 months post-procedure. A TLF event is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
        <time_frame>12-months post-procedure</time_frame>
        <population>Event-specific adjusted intent to treat (ITT) population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Target Lesion Failure (TLF)</title>
          <description>The primary endpoint for this study is the percentage of participants who experienced Target Lesion Failure (TLF) during the 12 months post-procedure. A TLF event is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
          <population>Event-specific adjusted intent to treat (ITT) population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36"/>
                    <measurement group_id="O2" value="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample sizes of 1,061 from the ELITE™ group and 531 from the CYPHER® group were planned to achieve 90 percent power at a 2.5 percent significance level using an one-sided equivalence test, assuming a 10 percent TLF rate in each group and the maximum allowable rate difference between the groups being 5 percent. The total sample size was increased to 1,770 patients to account for an approximately 90 percent compliance to clinical follow-up.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null inferiority hypothesis was that the upper limit of the 95% confidence interval is equal or greater than the non-inferiority margin 5%. The alternative non-inferiority hypothesis for this study assumed that the upper limit of the 95% confidence interval would be less than the non-inferiority margin 5%.</non_inferiority_desc>
            <param_type>Difference between TLF rates</param_type>
            <param_value>2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>5.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Lesion Success</title>
        <description>Lesion success is defined as the attainment of &lt; 50 percent residual stenosis (by Quantitative Coronary Angiography (QCA)) using any percutaneous method.</description>
        <time_frame>At procedure</time_frame>
        <population>ITT: All randomized participants regardless whether they received the intervention</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Lesion Success</title>
          <description>Lesion success is defined as the attainment of &lt; 50 percent residual stenosis (by Quantitative Coronary Angiography (QCA)) using any percutaneous method.</description>
          <population>ITT: All randomized participants regardless whether they received the intervention</population>
          <units>Percentage of success</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.549</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Device Success - Protocol Definition</title>
        <description>Device success is defined as achievement of a final residual diameter stenosis of &lt;50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. Protocol definition: Only protocol-defined study stents were included.</description>
        <time_frame>At procedure</time_frame>
        <population>Intent to Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Device Success - Protocol Definition</title>
          <description>Device success is defined as achievement of a final residual diameter stenosis of &lt;50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. Protocol definition: Only protocol-defined study stents were included.</description>
          <population>Intent to Treat population.</population>
          <units>Percentage of success</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>13.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>18.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Device Success - All CYPHER® Stents Included</title>
        <description>Device success is defined as achievement of a final residual diameter stenosis of &lt;50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. All CYPHER® Stents were included if the final residual stenosis was &lt;50%. Non-study CYPHER® Stents were also included.</description>
        <time_frame>At procedure</time_frame>
        <population>Intent to Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Device Success - All CYPHER® Stents Included</title>
          <description>Device success is defined as achievement of a final residual diameter stenosis of &lt;50 percent (by QCA), using the assigned device only. If QCA was not available, the visual estimate of diameter stenosis was used. Device success was based on the following two measurements. All CYPHER® Stents were included if the final residual stenosis was &lt;50%. Non-study CYPHER® Stents were also included.</description>
          <population>Intent to Treat population.</population>
          <units>Percentage of success</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Procedure Success</title>
        <description>Procedure success is defined as achievement of a final diameter stenosis of &lt; 50 percent (by QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion during the hospital stay.</description>
        <time_frame>At procedure during hospital stay</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Procedure Success</title>
          <description>Procedure success is defined as achievement of a final diameter stenosis of &lt; 50 percent (by QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion during the hospital stay.</description>
          <population>Intent to Treat</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.407</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Target Lesion Revascularization (TLR)</title>
        <description>TLR is defined as any “clinically-driven” repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic electrocardiogram (ECG) changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.</description>
        <time_frame>12 months post-procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Target Lesion Revascularization (TLR)</title>
          <description>TLR is defined as any “clinically-driven” repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic electrocardiogram (ECG) changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50"/>
                    <measurement group_id="O2" value="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.203</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>2.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Target Vessel Revascularization (TVR)</title>
        <description>TVR is defined as any &quot;clinically driven&quot; repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Target Vessel Revascularization (TVR)</title>
          <description>TVR is defined as any &quot;clinically driven&quot; repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis 50 percent by QCA.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13"/>
                    <measurement group_id="O2" value="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>5.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Target Vessel Failure (TVF)</title>
        <description>Target Vessel failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Target Vessel Failure (TVF)</title>
          <description>Target Vessel failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.99"/>
                    <measurement group_id="O2" value="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.166</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>6.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE)</title>
        <description>MAJOR ADVERSE CARDIAC EVENTS (MACE) consists of death, myocardial infarction, emergent bypass surgery, and target lesion revascularization.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE)</title>
          <description>MAJOR ADVERSE CARDIAC EVENTS (MACE) consists of death, myocardial infarction, emergent bypass surgery, and target lesion revascularization.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29"/>
                    <measurement group_id="O2" value="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>2.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF)</title>
        <description>A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>All randomized participants with lesions of more than 1 vessel and were followed for 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF)</title>
          <description>A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
          <population>All randomized participants with lesions of more than 1 vessel and were followed for 12 months</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.89"/>
                    <measurement group_id="O2" value="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>11.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.73</ci_lower_limit>
            <ci_upper_limit>24.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF)</title>
        <description>A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>All randomized participants who had diabetes and were followed up for 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF)</title>
          <description>A Target Lesion Failure is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.</description>
          <population>All randomized participants who had diabetes and were followed up for 12 months.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>5.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>10.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Bleeding Complications</title>
        <description>Bleeding complications include any bleeding events defined by THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI), Global Strategies for Opening Occluded Coronary Arteries (GUSTO), and “Protocol” definitions.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>All randomized participants who had 12 months follow-up and documented specific events</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Bleeding Complications</title>
          <description>Bleeding complications include any bleeding events defined by THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI), Global Strategies for Opening Occluded Coronary Arteries (GUSTO), and “Protocol” definitions.</description>
          <population>All randomized participants who had 12 months follow-up and documented specific events</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.08"/>
                    <measurement group_id="O2" value="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.61</ci_lower_limit>
            <ci_upper_limit>5.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Died</title>
        <description>Death incidences include both Cardiac and non-cardiac death.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>All randomized participants who had 12 months follow-up and documented specific events</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died</title>
          <description>Death incidences include both Cardiac and non-cardiac death.</description>
          <population>All randomized participants who had 12 months follow-up and documented specific events</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70"/>
                    <measurement group_id="O2" value="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.92</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Any Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction includes both Q-wave and WHO Non-Q Wave Myocardial Infarction events.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>All randomized participants who had 12 months follow-up and documented specific events</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction includes both Q-wave and WHO Non-Q Wave Myocardial Infarction events.</description>
          <population>All randomized participants who had 12 months follow-up and documented specific events</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80"/>
                    <measurement group_id="O2" value="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.801</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.73</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Stroke</title>
        <description>The stroke definition includes both hemorrhagic and non-hemorrhagic strokes.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>All randomized participants who had 12 months follow-up and documented specific events</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Stroke</title>
          <description>The stroke definition includes both hemorrhagic and non-hemorrhagic strokes.</description>
          <population>All randomized participants who had 12 months follow-up and documented specific events</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47"/>
                    <measurement group_id="O2" value="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.341</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>-0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition)</title>
        <description>Protocol defined Stent thrombosis include both Early and Late Thrombosis. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave MI, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring &gt; 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site-reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition)</title>
          <description>Protocol defined Stent thrombosis include both Early and Late Thrombosis. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave MI, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring &gt; 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site-reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47"/>
                    <measurement group_id="O2" value="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.14</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition)</title>
        <description>Academic Research Consortium (ARC) defines STENT THROMBOSIS as consisting of the following:
DEFINITE - Angiographic or pathologic confirmation;
PROBABLE - Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent;
POSSIBLE - Any unexplained death &gt; 30 days.
ARC Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points.</description>
        <time_frame>12 months post procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition)</title>
          <description>Academic Research Consortium (ARC) defines STENT THROMBOSIS as consisting of the following:
DEFINITE - Angiographic or pathologic confirmation;
PROBABLE - Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent;
POSSIBLE - Any unexplained death &gt; 30 days.
ARC Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93"/>
                    <measurement group_id="O2" value="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.668</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference between event rates</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.72</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition)</title>
        <description>Those ARC stent thromboses occurred between 0 and 30 days post-procedure are early stent thrombosis.</description>
        <time_frame>0-30 days post-procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition)</title>
          <description>Those ARC stent thromboses occurred between 0 and 30 days post-procedure are early stent thrombosis.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition)</title>
        <description>Those ARC stent thromboses occurred between 31 to 360 days post-procedure are late stent thrombosis.</description>
        <time_frame>31-360 days post-procedure</time_frame>
        <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>ELITE™</title>
            <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
          </group>
          <group group_id="O2">
            <title>CYPHER®</title>
            <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition)</title>
          <description>Those ARC stent thromboses occurred between 31 to 360 days post-procedure are late stent thrombosis.</description>
          <population>Event specific adjusted ITT population: All randomized participants excluding those with follow-up less than 330 days and without documented specific events during the 360 days post procedure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="428"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ELITE™</title>
          <description>CYPHER® ELITE™ Sirolimus-Eluting Stent System.</description>
        </group>
        <group group_id="E2">
          <title>CYPHER®</title>
          <description>CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>The deaths for the three patients were not MedDRA coded as &quot;death&quot; since these are based on site reported MedDRA coding to the underlying cause of death.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="99" subjects_affected="99" subjects_at_risk="452"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="452"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="452"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="452"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="452"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="452"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="452"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="452"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early by the Sponsor for business reasons. Hence the data was under powered for hypothesis testing. No definitive conclusions can be made from this data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amy Orlick, Associate Director Clinical Research</name_or_title>
      <organization>Cordis</organization>
      <phone>908-541-4347</phone>
      <email>AOrlick@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

